By Fineline Cube China-based Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793) has announced a partnership with compatriot firm Shanghai Pharmaceutical Co., Ltd. Under the agreement, Shanghai Pharma will become Luoxin’s strategic partner in China, providing a range of services including end delivery and marketing, import and export supply chain management, branding and academic promotion, and pre-marketing services for innovative drugs. The partnership will also include support in novel payment programs, professional tendering, and regulatory affairs. Financial details of the partnership were not disclosed.
Scope of Services
Shanghai Pharma will offer comprehensive support to Luoxin, enhancing its capabilities in several key areas. This includes end delivery and marketing services to improve market reach, import and export supply chain services to streamline operations, and branding and academic promotion services to enhance product visibility. Additionally, Shanghai Pharma will provide pre-marketing services for innovative drugs, support in novel payment programs, professional tendering, and regulatory affairs, ensuring a robust framework for Luoxin’s growth and development.
Future Outlook
The strategic partnership between Shandong Luoxin and Shanghai Pharma marks a significant step in enhancing Luoxin’s market position and operational efficiency. By leveraging Shanghai Pharma’s extensive experience and resources, Luoxin is well-positioned to expand its reach and deliver innovative solutions to the market.-Fineline Info & Tech